Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial
Open Access
Abstract
Introduction About 25% of patients with COVID-19 develop acute respiratory distress syndrome (ARDS) associated with a high release of pro-inflammatory cytokines such as interleukin-6 (IL-6). The aim of the SARICOR study is to demonstrate that early administration of sarilumab (an IL-6 receptor inhibitor) in hospitalised patients with COVID-19, pulmonary infiltrates and a high IL-6 or D-dimer serum level could reduce the progression of ARDS requiring high-flow nasal oxygen or mechanical ventilation (non-invasive or invasive). Methods and analysis Phase II, open-label, randomised, multicentre, controlled clinical trial to study the efficacy and safety of the administration of two doses of sarilumab (200 and 400 mg) plus best available therapy (BAT) in hospitalised adults with COVID-19 presenting cytokine release syndrome. This strategy will be compared with a BAT control group. The efficacy and safety will be monitored up to 28 days postadministration. A total of 120 patients will be recruited (40 patients in each arm). Ethics and dissemination The clinical trial has been approved by the Research Ethics Committee of the coordinating centre and authorised by the Spanish Agency of Medicines and Medical Products. If the hypothesis is verified, the dissemination of the results could change clinical practice by increasing early administration of sarilumab in adult patients with COVID-19 presenting cytokine release syndrome, thus reducing intensive care unit admissions. Trial registration number NCT04357860.Keywords
Funding Information
- Consejería de Salud, Junta de Andalucía (COVID-0013-2020)
This publication has 22 references indexed in Scilit:
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19New England Journal of Medicine, 2020
- Care for Critically Ill Patients With COVID-19JAMA, 2020
- Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19Journal of Medical Virology, 2020
- COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?Clinical and Experimental Rheumatology, 2020
- Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeuticsDrug Development Research, 2020
- Critical care crisis and some recommendations during the COVID-19 epidemic in ChinaIntensive Care Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Current Therapeutic Options in the Treatment of Rheumatoid ArthritisJournal of Clinical Medicine, 2019
- A practical guide to the monitoring and management of the complications of systemic corticosteroid therapyAllergy, Asthma & Clinical Immunology, 2013
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004